Organisation paid for research Program year 2025 Source: CMS Open Payments

Savin Medical Group LLC

Neither a doctor nor a teaching hospital

Research payments

$2,848,198

191 payments

Through program year 2025, Savin Medical Group LLC is reported as receiving $2,848,198 in research payments, across 191 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $122,581 13
2024 Research $477,360 24
2023 Research $50,718 8
2022 Research $737,749 17
2021 Research $946,815 30
2020 Research $232,541 56
2019 Research $280,434 43

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,763,481 63 payments
  2. Allergan Inc. $360,024 69 payments
  3. Amgen Inc. $294,864 11 payments
  4. AbbVie, Inc. $237,976 33 payments
  5. Braintree Laboratories, Inc. $144,996 9 payments
  6. Dr.Reddy's Laboratories,Inc. $46,858 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $678,723 9 payments
  2. An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $584,373 14 payments
  3. An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $380,463 11 payments
  4. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $176,992 14 payments
  5. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $174,912 26 payments
  6. ASCEND P3 AD Extension $154,627 2 payments
  7. Jak1 Dupilumab Comparator Study $78,829 18 payments
  8. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $74,130 2 payments
  9. A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $70,866 7 payments
  10. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $52,237 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record